ANTX Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AN2 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.30 |
| 52 Week High | US$22.22 |
| 52 Week Low | US$0.87 |
| Beta | -0.22 |
| 11 Month Change | 20.37% |
| 3 Month Change | 17.12% |
| 1 Year Change | -91.90% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -91.56% |
Recent News & Updates
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Nov 21
Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04Recent updates
We're Keeping An Eye On AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Nov 21Is AN2 Therapeutics (NASDAQ:ANTX) In A Good Position To Invest In Growth?
Jul 04Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Mar 23AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Dec 05AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans
Aug 20We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
May 09We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate
Feb 03We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely
Oct 21AN2 Therapeutics secures $17.8M contract from NIH
Sep 29We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth
Jul 01Shareholder Returns
| ANTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 28.7% | -3.8% | -1.0% |
| 1Y | -91.9% | 9.8% | 30.3% |
Return vs Industry: ANTX underperformed the US Pharmaceuticals industry which returned 8.7% over the past year.
Return vs Market: ANTX underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| ANTX volatility | |
|---|---|
| ANTX Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANTX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ANTX's weekly volatility has decreased from 17% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 41 | Eric Easom | www.an2therapeutics.com |
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials.
AN2 Therapeutics, Inc. Fundamentals Summary
| ANTX fundamental statistics | |
|---|---|
| Market cap | US$31.63m |
| Earnings (TTM) | -US$60.70m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs ANTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$60.70m |
| Earnings | -US$60.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANTX perform over the long term?
See historical performance and comparison